Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: To describe a patient with neuromyelitis optica (NMO) whose aquaporin 4 (AQP4) antibody levels increased following treatment with interferon beta. DESIGN: Prospective clinical and laboratory case report. SETTING: Institutional referral center for multiple sclerosis (MS). Patient One patient with an initial diagnosis of MS that was later revised to NMO. INTERVENTIONS: A course of interferon beta-1a followed by conventional immunosuppression. Blood samples were collected from the onset of treatment, and clinical and laboratory assessment was performed. MAIN OUTCOME MEASURES: Serum levels of AQP4 antibody and number and characteristics of neurological relapses. RESULTS: After 3 relapses during a 10-month period despite interferon beta-1a treatment, the diagnosis of AQP4 antibody-positive NMO was made and treatment was switched to prednisolone and methotrexate. The AQP4 antibody titers rose dramatically during treatment with interferon beta, and then fell when conventional immunosuppressive therapy was substituted; the patient has remained relapse-free for the subsequent years. CONCLUSIONS: Although previous articles have suggested that interferon beta may increase relapses in NMO, this is the first to illustrate an increase in AQP4 antibodies associated with such treatment.

Original publication

DOI

10.1001/archneurol.2010.188

Type

Journal article

Journal

Arch Neurol

Publication Date

08/2010

Volume

67

Pages

1016 - 1017

Keywords

Antibodies, Aquaporin 4, Female, Humans, Immunologic Factors, Interferon-beta, Middle Aged, Neuromyelitis Optica, Secondary Prevention